| Autor: |
Leal, Christianne Tolêdo de Souza, Souza, Viviane Angelina de, Ferreira, Júlia Diniz, Zanini, Alexandre, Santos, Kelli Borges dos, Ezequiel, Danielle Guedes Andrade, Neto, Abrahão Elias Hallack |
| Předmět: |
|
| Zdroj: |
Clinical Transplantation; Jul2024, Vol. 38 Issue 7, p1-3, 3p |
| Abstrakt: |
Gonadal dysfunction, the most frequent endocrine complication in both sexes after autologous hematopoietic cell transplant (HCT) could increase bone loss and sarcopenia, a disease characterized by reduced muscle strength and mass. Sarcopenia is associated with worse survival, lower remission rates, and progression‐free survival in patients with lymphoma after HCT. Low bone mass affected approximately 20% of the transplanted patients within 2 years and harms quality of life. This study was conducted in a single center and identified a strong relationship with patients transplanted more recently by LEC (lomustine, etoposide, and cyclophosphamide) conditioning regimen with sarcopenia. Peripheral neuropathy and bone mass changes were also associated with sarcopenia as well, suggesting a relationship with muscle strength loss. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text